BANK VONTOBEL/CALL/BIONTECH ADR/130/0.1/20.12.24 Share Price

Warrant

PD34V

DE000VM7QD48

Market Closed - Euronext Paris 10:00:01 16/05/2024 pm IST
0.221 EUR +11.06% Intraday chart for BANK VONTOBEL/CALL/BIONTECH ADR/130/0.1/20.12.24
Current month+6.83%
1 month+3.79%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
16/24/16 0.221 +11.06%
15/24/15 0.199 +2.05%
14/24/14 0.195 -10.96%
13/24/13 0.219 -6.81%
10/24/10 0.235 +5.38%

Real-time Euronext Paris

Last update May 16, 2024 at 10:00 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer Vontobel Vontobel
PD34V
ISINDE000VM7QD48
Date issued 03/01/2024
Strike 130 $
Maturity 20/12/2024 (218 Days)
Parity 10 : 1
Emission price 0.95
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 1.465
Lowest since issue 0.171
Delta0.19x
Omega 7.172
Premium42.37x
Gearing38.7x
Moneyness 0.7154
Difference Strike 37.18 $
Difference Strike %+28.60%
Spread 0.01
Spread %4.42%
Theoretical value 0.2210
Implied Volatility 37.54 %
Total Loss Probability 88.21 %
Intrinsic value 0.000000
Present value 0.2210
Break even 132.40 €
Theta-0.01x
Vega0.02x
Rho0.01x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
84.83 EUR
Average target price
105.4 EUR
Spread / Average Target
+24.23%
Consensus
  1. Stock Market
  2. Warrants
  3. PD34V Warrant
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW